POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES.

2023

https://researcherprofiles.org/profile/425025837

X. Baraliakos, A. Deodhar, D. Van der Heijde, M. Magrey, W. P. Maksymowych, T. Tomita, H. Xu, M. Oortgiesen, U. Massow, C. Fleurinck, A. Ellis, T. Vaux, J. Smith, A. Marten, L. S. Gensler

Center for Advancing Scholarship in Education

Center for Faculty Educators

POS1103 BIMEKIZUMAB MAINTAINED IMPROVEMENTS IN EFFICACY ENDPOINTS AND HAD A CONSISTENT SAFETY PROFILE THROUGH 52 WEEKS IN PATIENTS WITH NON-RADIOGRAPHIC AND RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: RESULTS FROM TWO PARALLEL PHASE 3 STUDIES.